ZMZoltan Molnar

Zoltan Molnar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zoltan Molnar has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Aditi Singh

    The Wellcome–Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, UK

    1 shared publication
  • Andrew G. Demaine

    Renal Unit and Diabetes Clinical Research Unit, Derriford Hospital, Plymouth, PL6 8DH, UK

    1 shared publication
  • Ann B. Millward

    Renal Unit and Diabetes Clinical Research Unit, Derriford Hospital, Plymouth, PL6 8DH, UK

    1 shared publication
  • Arun Mahesh

    The Wellcome–Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, UK

    1 shared publication
  • Chris Baxter

    Genomics Core Technology Unit, Faculty of Medicine and Health Sciences, Queen’s University Belfast, Belfast, UK

    1 shared publication
  • Clara Radulescu

    The Wellcome–Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University, Belfast, UK

    1 shared publication

Latest Publications

  • Open Access

    Mini-XT, a miniaturized tagmentation-based protocol for efficient sequencing of SARS-CoV-2

    by Marc Fuchs, Clara Radulescu, Miao Tang, Arun Mahesh, Deborah Lavin, Syed Umbreen, James McKenna, Mark Smyth, Eilís McColgan, Zoltan Molnar, et al.

    Background: The COVID-19 pandemic has highlighted the importance of whole genome sequencing (WGS) of SARS-CoV-2 to inform public health policy. By enabling definition of lineages it facilitates tracking of the global spread of the virus. The evolution of new variants can be monitored and knowledge of specific mutations provides insights into the mechanisms through which the virus increases transmissibility or evades immunity. To date almost 1 million SARS-CoV-2 genomes have been sequenced by members of the COVID-19 Genomics UK (COG-UK) Consortium. To achieve similar feats in a more cost-effective and sustainable manner in future, improved high throughput virus sequencing protocols are required. We have therefore developed a miniaturized library preparation protocol with drastically reduced consumable use and costs. Results: We present the ‘Mini-XT’ miniaturized tagmentation-based library preparation protocol available on protocols.io (10.17504/protocols.io.bvntn5en). SARS-CoV-2 RNA was amplified using the ARTIC nCov-2019 multiplex RT-PCR protocol and purified using a conventional liquid handling system. Acoustic liquid transfer (Echo 525) was employed to reduce reaction volumes and the number of tips required for a Nextera XT library preparation. Sequencing was performed on an Illumina MiSeq. The final version of Mini-XT has been used to sequence 4384 SARS-CoV-2 samples from N. Ireland with a COG-UK QC pass rate of 97.4%. Sequencing quality was comparable and lineage calling consistent for replicate samples processed with full volume Nextera DNA Flex (333 samples) or using nanopore technology (20 samples). SNP calling between Mini-XT and these technologies was consistent and sequences from replicate samples paired together in maximum likelihood phylogenetic trees. Conclusions: The Mini-XT protocol maintains sequence quality while reducing library preparation reagent volumes eightfold and halving overall tip usage from sample to sequence to provide concomitant cost savings relative to standard protocols. This will enable more efficient high-throughput sequencing of SARS-CoV-2 isolates and future pathogen WGS.


  • Open Access

    p21WAF1/CIP1Expression is Differentially Regulated by Metformin and Rapamycin

    by Zoltan Molnar, Ann B. Millward, Wai Tse, Andrew G. Demaine

    The mammalian target of rapamycin (mTOR) pathway plays an important role in the development of diabetic nephropathy and other age-related diseases. One of the features of DN is the elevated expression of p21WAF1/CIP1. However, the importance of the mTOR signalling pathway in p21 regulation is poorly understood. Here we investigated the effect of metformin and rapamycin on mTOR-related phenotypes in cell lines of epithelial origin. This study reports that metformin inhibits high glucose-induced p21 expression. High glucose opposed metformin in regulating cell size, proliferation, and protein synthesis. These effects were associated with reduced AMPK activation, affecting downstream mTOR signalling. However, the inhibition of the mTOR pathway by rapamycin did not have a negative effect on p21 expression, suggesting that metformin regulates p21 upstream of mTOR. These findings provide support for the hypothesis that AMPK activation may regulate p21 expression, which may have implications for diabetic nephropathy and other age-related pathologies.